Turning Point Benefit Group, Inc. Anavex Life Sciences Corp. Transaction History
Turning Point Benefit Group, Inc.
- $191 Billion
- Q4 2025
A detailed history of Turning Point Benefit Group, Inc. transactions in Anavex Life Sciences Corp. stock. As of the latest transaction made, Turning Point Benefit Group, Inc. holds 150 shares of AVXL stock, worth $546. This represents 0.0% of its overall portfolio holdings.
Number of Shares
150Holding current value
$546% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding AVXL
# of Institutions
214Shares Held
32.1MCall Options Held
1.82MPut Options Held
1.09M-
Black Rock Inc. New York, NY6.39MShares$23.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.03MShares$18.3 Million0.0% of portfolio
-
State Street Corp Boston, MA3.29MShares$12 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA2.03MShares$7.38 Million0.0% of portfolio
-
Two Sigma Investments, LP New York, NY1.04MShares$3.77 Million0.02% of portfolio
About ANAVEX LIFE SCIENCES CORP.
- Ticker AVXL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,942,800
- Market Cap $284M
- Description
- Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...